The 67 rating InvestorsObserver gives to Novavax, Inc. (NVAX) stock puts it near the middle of the Biotechnology industry. In addition to scoring higher than 66 percent of stocks in the Biotechnology industry, NVAXs 67 overall rating means the stock scores better than 67 percent of all stocks.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 67 means the stock is more attractive than 67 percent of stocks.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

Novavax, Inc. (NVAX) stock is lower by -5.21% while the S&P 500 has gained 0.13% as of 3:24 PM on Thursday, May 21. NVAX has fallen -$2.75 from the previous closing price of $52.81 on volume of 4,757,063 shares. Over the past year the S&P 500 has risen 4.17% while NVAX has gained 727.44%. NVAX lost -$4.14 per share the over the last 12 months.

To see the top 5 stocks in Biotechnology click here.

Excerpt from:
Where Does Novavax, Inc. (NVAX) Stock Fall in the Biotechnology Field? - InvestorsObserver